Evidence map›Paper›PMID 25446990›Full record

ReviewBiochimica et biophysica acta2015

Resveratrol and cancer: Challenges for clinical translation.

Chandra K Singh, Mary A Ndiaye, Nihal Ahmad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 2 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 260 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Resveratrol againstTropical medicine and infectious disease · 2023
    Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chandra K SinghDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA.
Mary A NdiayeDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA.
Nihal AhmadDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA. Electronic address: nahmad@wisc.edu.
University of Wisconsin–Madison · US

Funding

Role of SIRT1 in melanocyte biology and melanocyte transformationR01CA176748 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2013 to 2017
$1.6M
Enhancing Bioavailability of ResveratrolR21CA149560 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL, BAILEY, HOWARD H. · 2010 to 2011
$496k
Resveratrol-Zinc Combination for Prostate CancerR21CA176867 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2013 to 2014
$355k
NCI NIH HHS R01CA149560NCI NIH HHS R01 CA176748NCI NIH HHS R01CA176748NCI NIH HHS R01CA176867NCI NIH HHS R21 CA149560NCI NIH HHS R21 CA176867
6 · The paper itself

Abstract

Significant work has been done towards identifying the health-beneficial effects of the grape antioxidant resveratrol in a variety of bioassay- and disease- models, with much research being focused on its possible application to cancer management. Despite the large number of preclinical studies dealing with different aspects of the biological effects of resveratrol, its translation to clinics is far from reality due to a variety of challenges. In this review, we discuss the issues and questions associated with resveratrol becoming an effective in vivo anticancer drug, from basic metabolic issues to the problems faced by incomplete understanding of the mechanism(s) of action in the body. We also explore efforts taken by researchers, both public and private, to contend with some of these issues. By examining the published data and previous clinical trials, we have attempted to identify the problems and issues that hinder the clinical translation of resveratrol for cancer management. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

Indexed as

Clinical Trials as TopicAnimalsAntineoplastic AgentsHumansNeoplasmsResveratrolStilbenesTranslational Research, BiomedicalAntineoplastic AgentsResveratrolStilbenesCancerClinical trialResveratrol

Identifiers

PMID25446990
PMCPMC4380791
OpenAlexW2082079559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.